COVAX 19
Alternative Names: Adjuvanted COVID-2019 vaccine - Vaxine; Advax-CpG55.2 adjuvanted recombinant spike protein - Vaxine; COVAX-19™ vaccine; SpikoGen; Spikogen/Covax-19Latest Information Update: 14 Aug 2024
At a glance
- Originator Vaxine
- Developer CinnaGen; GeneCure Biotechnologies; Vaxine
- Class COVID-19 vaccines; Subunit vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered COVID 2019 infections
Most Recent Events
- 01 May 2024 Phase-I clinical trials in COVID-2019 infections (Prevention) in Australia (Sublingual) (NCT06355232)
- 09 Apr 2024 Vaxine plans a phase I trial for COVID-2019 infections (Prevention) in Australia (Sublingual) (NCT06355232)
- 28 Sep 2023 No recent reports of development identified for phase-I development in COVID-2019-infections in USA (IM, Injection)